Patients with DME who are treated using aflibercept are more likely to experience acute kidney injury or hospitalisation due to renal events than those treated with ranibizumab. Using a target ...

The rate of offers per candidate represents a threefold increase compared with 2015. (HealthDay News) — The number of kidney transplants performed annually in the United States has increased ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.

No significant difference seen in urodynamic testing results between TPTNS and rTMS groups. (HealthDay News) — For female patients with multiple sclerosis (MS), transcutaneous posterior tibial ...

Geographic disparities seen, with greater percentage of cardiovascular deaths attributable to di-2-ethylhexylphthalate exposure for South Asia, Middle East. (HealthDay News) — Di-2 ...

Addition of revascularization to optimized medical therapy not beneficial in patients with carotid stenosis ≥50 percent and low or intermediate predicted stroke risk.

SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

(HealthDay News) — The U.S. Department of Health and Human Services and the National Institutes of Health announced a new initiative called “Generation Gold Standard” to develop next-generation, ...

The combination of toripalimab, nimotuzumab, and chemotherapy has shown promise as neoadjuvant treatment for patients with high-risk, locally advanced penile cancer, according to researchers.

Diabetic foot ulcer outcomes such as amputation and premature death are more likely in hospitalized patients with ESKD. Among patients with diabetic foot ulcer, those with end-stage kidney disease ...

Now, as the new commissioner of the U.S. Food and Drug Administration (FDA), he's wasting no time charting a new course for the agency.